Current Controversies in Oncology
Current Controversies in Oncology and Current Insights in Oncology articles provide a forum for the exchange of views on topical issues in the field of oncology. The opinions expressed are those of the authors alone. They do not necessarily reflect the views of the Editor or ASCO.
Aug 10, 2016
Drs. Bruce D. Minsky and Bengt Glimelius debate the use of adjuvant treatment for R0, tumor-free rectal carcinoma following neoadjuvant treatment, with an introduction by Dr. Bertram Wiedenmann.
Jun 29, 2016
Drs. David P. Ryan and Edward A. Levine debate the use of CRS/HIPEC in patients with peritoneal metastases from colorectal cancer. Introduction by Dr. Paul H. Sugarbaker.
Apr 26, 2016
Americans are not dying well. Jeanie M. Youngwerth, MD, and D. Ross Camidge, MD, PhD, discuss the use of cancer therapy in tandem with palliative care in this article, with an introduction by Daniel W. Bowles, MD.
Feb 23, 2016
Dr. Robert Rifkin and Dr. Huub Schellekens provide an excellent discussion of the opportunities presented by biosimilar agents and several of the misconceptions or myths that have arisen around their development and use in oncology practice.
Dec 14, 2015
A powerful tool for genomic characterization of cancer is next-generation sequencing. There is an increasing interest in the role of NGS in improving the management of metastatic renal cell carcinoma.
Oct 15, 2015
There have been significant advances in the treatment of metastatic colorectal cancer. New chemotherapy has improved survival and response rates. Advances in surgical technique and expanded criteria for resectability of liver metastases have further improved survival rates.
Aug 18, 2015
Drs. Manisha Palta, Brian G. Czito, and Christopher G. Willett discuss the neoadjuvant chemoradiation approach to clinically staged T2NO adenocarcinoma of the GEJ.
Jun 30, 2015
Each year, over 1.6 million Americans and 14 million people worldwide are diagnosed with cancer. Further, cancer causes the deaths of 600,000 people annually in the United States and over eight million people globally. It is estimated that only 5% to 10%...
Apr 22, 2015
In this edition of Current Controversies in Oncology, expert hepatobiliary surgical oncologists debate the added benefit of neoadjuvant therapy for resectable hepatic colorectal metastases. While few would downplay the option of systemic therapy for a patient with bilobar metastases....
Feb 24, 2015
Jeff P. Sharman, MD, on why traditional chemoimmunotherapy with FCR should still be considered for ongoing use as an effective therapy: “If a fit younger patient has a favorable risk profile, intense chemoimmunotherapy may be the best route for long-term disease control—and possibly cure.”